BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23665330)

  • 1. Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model.
    Kaylani SZ; Xu J; Srivastava RK; Kopelovich L; Pressey JG; Athar M
    Biochem Biophys Res Commun; 2013 Jun; 435(4):557-61. PubMed ID: 23665330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.
    Srivastava RK; Kaylani SZ; Edrees N; Li C; Talwelkar SS; Xu J; Palle K; Pressey JG; Athar M
    Oncotarget; 2014 Dec; 5(23):12151-65. PubMed ID: 25432075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P; Hu W; Liu C; Li L
    Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism.
    Srivastava RK; Guroji P; Jin L; Mukhtar MS; Athar M
    Mol Carcinog; 2022 Aug; 61(8):737-751. PubMed ID: 35472745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
    McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
    Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog signal inhibitor forskolin suppresses cell proliferation and tumor growth of human rhabdomyosarcoma xenograft.
    Yamanaka H; Oue T; Uehara S; Fukuzawa M
    J Pediatr Surg; 2011 Feb; 46(2):320-5. PubMed ID: 21292081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells.
    Srivastava RK; Li C; Khan J; Banerjee NS; Chow LT; Athar M
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24583-24592. PubMed ID: 31732667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.
    Zuo M; Rashid A; Churi C; Vauthey JN; Chang P; Li Y; Hung MC; Li D; Javle M
    Br J Cancer; 2015 Mar; 112(6):1042-51. PubMed ID: 25742482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
    Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
    Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
    Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth.
    Couderc C; Poncet G; Villaume K; Blanc M; Gadot N; Walter T; Lepinasse F; Hervieu V; Cordier-Bussat M; Scoazec JY; Roche C
    Am J Pathol; 2011 Jan; 178(1):336-44. PubMed ID: 21224070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
    Graab U; Hahn H; Fulda S
    Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclopamine treatment of full-blown Hh/Ptch-associated RMS partially inhibits Hh/Ptch signaling, but not tumor growth.
    Ecke I; Rosenberger A; Obenauer S; Dullin C; Aberger F; Kimmina S; Schweyer S; Hahn H
    Mol Carcinog; 2008 May; 47(5):361-72. PubMed ID: 17963245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
    Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
    J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin: a central node of complex signaling cascades.
    Dobashi Y; Watanabe Y; Miwa C; Suzuki S; Koyama S
    Int J Clin Exp Pathol; 2011 Jun; 4(5):476-95. PubMed ID: 21738819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.